Sanjay Gandhi to Prostatic Neoplasms
This is a "connection" page, showing publications Sanjay Gandhi has written about Prostatic Neoplasms.
Connection Strength
0.232
-
Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M, Penson D. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Urology. 2005 Oct; 66(4):835-9.
Score: 0.048
-
Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J Urol. 2005 Aug; 174(2):547-52; discussion 552.
Score: 0.048
-
Unger HA, Kane RD, Fox KM, Gandhi S, Alzola C, Lamerato L, Newling D, Kumar S. Relative importance of PSA in prostate cancer treatment. Urol Oncol. 2005 Jul-Aug; 23(4):238-45.
Score: 0.047
-
Rosenfeld B, Roth AJ, Gandhi S, Penson D. Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psychooncology. 2004 Nov; 13(11):800-7.
Score: 0.045
-
Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol. 2004 Jun; 171(6 Pt 1):2250-4.
Score: 0.044